Cerebrovascular mortality + morbidity · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
Antihypertensive drug therapy may leads to lower cerebrovascular mortality + morbidity compared with control (low certainty).
1 finding from 1 review
Coronary heart disease mortality + morbidity · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
Antihypertensive drug therapy showed no clear difference in coronary heart disease mortality + morbidity compared with control (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
It is very uncertain whether antihypertensive drug therapy changes withdrawal due to adverse events compared with control (very low certainty).
1 finding from 1 review
Decrease in SBP5 at end of 1 year · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
1 finding from 1 review
Decrease in DBP6 at end of 1 year · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
1 finding from 1 review
Sudden cardiac death · patients with hypertension
Antihypertensive pharmacotherapy showed no clear difference in sudden cardiac death ( compared with control (moderate certainty).
1 finding from 1 review
Non‐fatal MI · patients with hypertension
Antihypertensive pharmacotherapy probably leads to lower non‐fatal myocardial infarction ( compared with control (moderate certainty).
1 finding from 1 review
Fatal myocardial infarction ( · patients with hypertension
Antihypertensive pharmacotherapy probably leads to lower fatal myocardial infarction ( compared with control (moderate certainty).
1 finding from 1 review
Total mortality · adults with primary hypertension
First‐line angiotensin converting enzyme inhibitor probably leads to lower total mortality compared with placebo (moderate certainty).
1 finding from 1 review
Stroke · adults with primary hypertension
First‐line angiotensin converting enzyme inhibitor may leads to lower total stroke compared with placebo (low certainty).
1 finding from 1 review
Total coronary heart disease · adults with primary hypertension
First‐line angiotensin converting enzyme inhibitor probably leads to lower total coronary heart disease compared with placebo (moderate certainty).
1 finding from 1 review
Cardiovascular events · adults with primary hypertension
First‐line angiotensin converting enzyme inhibitor probably leads to lower total cardiovascular events compared with placebo (moderate certainty).
1 finding from 1 review
Cardiovascular morbidity Combined endpoint: necessity of reinstating antihypertensive therapy and severe cardiovascular complications · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review
Intervention not reported
Angiotensin receptor blocker (high‐ versus medium‐dose) · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review
Intervention not reported
Angiotensin receptor blocker (medium‐ versus low‐dose) · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review
Intervention not reported
Angiotensin‐converting enzyme inhibitor · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Angiotensin receptor blocker (high‐ versus low‐dose) · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review
Diastolic blood pressure (mmHg), change from baseline · Adults (any age/sex) with chronic periodontitis (>=5 teeth remaining; PPD >4 mm), with or without hypertension
Intensive periodontal treatment (subgingival SRP with or without… probably leads to lower change in diastolic blood pressure (DBP, mmHg) compared with supra-gingival scaling (moderate certainty).
3 findings from 1 review
Endothelial function (flow-mediated dilation) · Adults (any age/sex) with chronic periodontitis (>=5 teeth remaining; PPD >4 mm), with or without hypertension
Intensive periodontal treatment (subgingival SRP with or without… led to higher endothelial function (flow-mediated dilation) compared with supra-gingival scaling; GRADE not reported.
3 findings from 1 review
Adverse events (participants with adverse events or withdrawals due to adverse events) · Adults (any age/sex) with chronic periodontitis (>=5 teeth remaining; PPD >4 mm), with or without hypertension
1 finding from 1 review